Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000950170-25-059303
Filing Date
2025-04-28
Accepted
2025-04-28 16:10:03
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A eypt_defa_14a_04-26-2025.htm DEFA14A 23430
2 GRAPHIC img110690558_0.jpg GRAPHIC 358271
3 GRAPHIC img110690558_1.jpg GRAPHIC 296463
  Complete submission text file 0000950170-25-059303.txt   926247
Mailing Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472
Business Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472 617-926-5000
EyePoint Pharmaceuticals, Inc. (Filer) CIK: 0001314102 (see all company filings)

EIN.: 262774444 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-51122 | Film No.: 25880405
SIC: 3826 Laboratory Analytical Instruments
(CF Office: 08 Industrial Applications and Services)